证券代码：688739 证券简称：成大生物 公告编号：2023-029 辽宁成大生物股份有限公司 第五届监事会第三次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 （一）审议通过《公司 2023 年半年度报告及摘要》 公司 2023 年半年度报告的编制和审议程序符合法律、行政法规和中国证监 会的规定，所包含的信息从各个方面真实、准确、完整地反映出公司报告期内的 经营成果和财务状况等事项。所载资料不存在任何虚假记载、误导性陈述或重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 表决结果:同意票 3 票、反对票 0 票、弃权票 0 票 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《辽宁成大生物股份有限公司 2023 年半年度报告》及《辽宁成大生物股份有限 公司 2023 年半年度报告摘要》。 （二）审议通过《2023 年半年度募集资金存放与实际使用情况的专项报告》 根据中国证监会《上海证券交易所科创板股票上市规则》《上市公司监管指 引第 ...

证券代码：688739 证券简称：成大生物 公告编号：2023-028 辽宁成大生物股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》及《辽宁成大生物股份有限公司募集资金管 理制度》等相关规定，辽宁成大生物股份有限公司（以下简称"成大生物"或"公 司"）董事会对公司首次公开发行股票募集资金在 2023 年上半年的使用情况进行 了全面核查，并出具了《2023 年半年度募集资金存放与实际使用情况的专项报 告》。相关情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会于 2021 年 9 月 14 日出具的《关于同意辽宁成 大生物股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3019 号）， 公司首次公开发行人民币普通股（A） ...

辽宁成大生物股份有限公司 董事会 关于 2023 年半年度募集资金存放与实际使用情况的专项报告的独立意见 报告期内，公司募集资金存放与实际使用情况符合《上海证券交易所科创板 股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和《公司章程》《募集资金管理制度》等公司制度文件的规定；公司 对募集资金进行了专户存储和专项使用，募集资金投资用途及内部结构变更等事 项均履行了必要且合规的决策程序，并及时履行了相关信息披露义务，不存在变 相改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金的情形。 因此，我们一致同意公司 2023 年半年度募集资金存放与实际使用情况专项 报告事宜。 独立董事：陈克兢 张克坚 刘晓辉 辽宁成大生物股份有限公司 独立董事关于第五届董事会第四次会议 相关事项的独立意见 我们作为辽宁成大生物股份有限公司 (以下简称"公司")的独立董事，根 据《中华人民共和国公司法》《上市公司独立董事规则》《上海证券交易所科创板 股票上市规则》《公司章程》及公司《独立董事工作制度》等有关规定 ...

证券代码：688739 证券简称：成大生物 公告编号：2023-027 辽宁成大生物股份有限公司 关于收到董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日收到 公司董事长李宁先生提交的《关于提议辽宁成大生物股份有限公司回购公司股 份的函》。提议主要内容如下： 一、提议回购股份的原因和目的 基于对公司未来持续发展的信心和对公司价值的认可，为了维护广大投资 者利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展，有效地 将股东利益、公司利益和员工个人利益紧密结合在一起，公司董事长李宁先生 提议公司通过集中竞价交易方式回购公司部分股份，在未来适宜时机用于实施 员工持股计划或股权激励。 二、提议内容 1、回购股份的种类：公司发行的人民币普通股（A 股）。 2、回购股份的用途：用于员工持股计划或股权激励。若公司未能在股份回 购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用的已回购 股份将予以注销， ...

证券代码：688739 证券简称：成大生物 公告编号：2023-022 辽宁成大生物股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 15 日(星期一) 至 5 月 19 日(星期五） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 lncdsw@cdbio.cn 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和 会议召开时间：2023 年 5 月 22 日(星期一) 上午 09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间 ...

三、 其他提醒事项 需提醒投资者关注的关于公司报告期经营情况的其他重要信息 □适用 √不适用 四、 季度财务报表 (一)审计意见类型 □适用 √不适用 (二)财务报表 2023 年 3 月 31 日 编制单位:辽宁成大生物股份有限公司 | --- | --- | --- | |--------------------|------------------------------|-------------------------------| | 项目 | 2023 年 3 月 31 日 | 2022 年 12 月 31 日 | | 流动资产： | | | | 货币资金 | 4,457,113,803.32 | 5,796,844,904.91 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 1,255,836,919.33 | - | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 1,084,607,352.08 | 1,111,351,962.10 | | 应收款项融资 | | | | 预付款项 | 37,417,786.33 | 25,149 ...

证券代码：688739 证券简称：成大生物 公告编号：2023-014 辽宁成大生物股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 04 月 24 日(星期一) 上午 09:00- 10:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （一） 会议召开时间：2023 年 04 月 24 日上午 09:00-10:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 17 日(星期一) 至 04 月 21 日(星期 五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 lncdsw@cdbio.cn 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 辽宁成大生物股份有限公司（以下简称"公司"）已于 2 ...

R&D Investment and Innovation - The company applied for 61 new intellectual property rights during the reporting period, including 27 invention patent applications and received 23 patent authorizations[4]. - Total R&D investment amounted to approximately CNY 303.13 million, a decrease of 2.65% compared to the previous year, with capitalized R&D investment increasing by 24.43% to CNY 91.67 million[5]. - The proportion of total R&D investment to operating income increased by 1.79 percentage points to 16.70%[5]. - The company has a total of 183 R&D personnel, with an average salary of CNY 19.15 million, up from CNY 17.61 million in the previous year[8]. - The company is actively developing multiple vaccine platforms, including bacterial, viral, and multivalent vaccines, with a focus on innovative combined vaccines[12]. - The company has completed the construction of its recombinant protein vaccine technology platform and is researching various vaccine types, including B group meningococcal vaccines[12]. - The company is actively exploring the construction of an mRNA vaccine technology platform, alongside its existing platforms, to enhance its R&D capabilities[16]. - The company has established three major R&D technology platforms: bacterial vaccines, viral vaccines, and multi-valent vaccines, with nearly 200 R&D personnel in dedicated centers in Beijing and Shenyang[16]. - The company is advancing several vaccine projects, including the quadrivalent chicken embryo influenza virus split vaccine and the freeze-dried human rabies vaccine, both in phase III clinical trials[39]. - The company is advancing multiple vaccine projects, including the b-type influenza vaccine and the 20-valent pneumococcal conjugate vaccine, which are in various clinical stages[52]. - The company is focusing on core human vaccine business and actively exploring new vaccine varieties, technologies, and platforms for investment and R&D cooperation opportunities[198]. Market Performance and Sales - The main products sold during the reporting period were human rabies vaccine (Vero cells) and human inactivated Japanese encephalitis vaccine (Vero cells), with a decline in revenue for the rabies vaccine due to market competition and environmental factors[31]. - Revenue from the human inactivated Japanese encephalitis vaccine significantly increased compared to the previous year, attributed to the completion of workshop system upgrades and gradual market recovery[31]. - Domestic sales of the human rabies vaccine decreased due to declining demand and intensified competition, while the Japanese encephalitis vaccine contributed positively to sales performance[31]. - The company has administered over 400 million doses of its rabies vaccine, with a user base exceeding 100 million, highlighting its market penetration[30]. - The company maintained its leading position in the human rabies vaccine market, which contributed to stabilizing its operational performance amid competitive pressures[194]. - The company focused on enhancing sales promotion for human rabies vaccines in the second half of the year, resulting in a noticeable recovery in sales towards the end of the year[167]. Financial Performance - The company's operating revenue for 2022 was ¥1,814,998,630.37, a decrease of 13.08% compared to ¥2,088,043,469.78 in 2021[156]. - The net profit attributable to shareholders for 2022 was ¥714,020,336.78, down 20.00% from ¥892,490,658.44 in the previous year[156]. - The net profit after deducting non-recurring gains and losses was ¥665,235,943.06, a decrease of 22.87% compared to ¥862,518,502.00 in 2021[156]. - The net cash flow from operating activities was ¥546,491,870.30, an increase of 7.92% from ¥506,376,172.18 in 2021[156]. - The company's total assets at the end of 2022 were ¥10,055,750,519.36, reflecting a 2.69% increase from ¥9,792,731,456.06 at the end of 2021[156]. - The net assets attributable to shareholders increased by 3.18% to ¥9,649,585,884.87 from ¥9,352,015,548.09 in 2021[156]. - The basic earnings per share for 2022 were ¥1.71, a decrease of 26.92% from ¥2.34 in 2021[156]. - The diluted earnings per share also stood at ¥1.71, reflecting a decrease of 26.92% compared to ¥2.34 in the previous year[156]. Risk Management and Compliance - The company faces risks related to long-term technology iteration, emphasizing the need for continuous R&D investment to maintain its competitive edge[21]. - The company is implementing measures to mitigate risks from intensified market competition, including optimizing its marketing network and enhancing brand recognition[30]. - The company has established a comprehensive management mechanism for cooperation with global academic institutions and enterprises to ensure efficient project collaboration[16]. - The company emphasizes compliance and risk management to enhance its ability to respond to regulatory requirements[65]. - The company has outlined various risks and countermeasures in the management discussion and analysis section of the report[127]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[132]. Corporate Governance and Management - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and senior management to ensure effective internal control[67]. - The company organized 2 shareholder meetings during the reporting period, ensuring compliance with relevant laws and regulations to protect shareholders' rights[105]. - The company has not reported any special arrangements for corporate governance in the annual report[142]. - The company is focusing on talent management and recruitment to strengthen its workforce and improve organizational structure[65]. - The company has optimized its compensation management system and promoted performance management, significantly boosting employee motivation[199]. - The company is increasing recruitment efforts for high-quality talent and advancing the construction of a reserve cadre team for long-term development[199]. Production and Quality Management - The company has completed Phase I clinical trials for the ACYW135 meningococcal polysaccharide conjugate vaccine and the varicella live attenuated vaccine[77]. - The company successfully obtained approval for the inactivated Japanese encephalitis vaccine pre-filled syringe formulation, expanding its product offerings to meet market demand[194]. - The company completed the system upgrade of the Japanese encephalitis inactivated vaccine workshop, improving production efficiency and successfully starting commercial production[199]. - The company maintained its leading position in the human rabies vaccine market with 515 million doses released, comprising 227 batches[199]. - The company is committed to continuous improvement in quality management to ensure stable vaccine production[199]. - The company successfully passed five GMP inspections by provincial and higher-level drug regulatory authorities, achieving a 100% batch release rate for its vaccine products[199].

Group 1: Market Overview - The annual issuance of rabies vaccines in the industry is approximately 70 to 80 million doses, indicating a stable demand for human rabies vaccines due to their essential nature [1][2]. - The market for human rabies vaccines is expected to maintain steady growth, driven by increasing disposable income and public awareness regarding rabies prevention [2][3]. Group 2: Impact of COVID-19 - The COVID-19 pandemic has caused a temporary decline in market demand due to restricted activities of people and pets, leading to fewer rabies exposure incidents [1][2]. - Despite the pandemic's impact, the company remains confident in achieving its operational goals and creating greater value in 2022 [2][3]. Group 3: Company Performance and Strategy - The company has established a technical platform for the large-scale cultivation of various viral vaccines, with its human rabies vaccine entering Phase III clinical trials [2][3]. - The company aims to enhance its market position by leveraging its production technology, immunization procedures, and brand value, despite increased competition in the rabies vaccine market [2][4]. Group 4: Future Projections - The company anticipates that the market share of diploid rabies vaccines will increase, although production efficiency and pricing may limit this growth [2][3]. - The company plans to invest 1.4 billion yuan in the commercialization base for the 15-valent HPV vaccine, with a construction period of four years [3][4]. Group 5: Sales and Marketing - The company has increased its sales expenses in 2021 to strengthen its market promotion efforts in response to intensified competition [4][5]. - The sales team operates on a direct sales model, focusing on public health centers, and plans to expand as new products are launched [5][6]. Group 6: Vaccine Development - The company is conducting clinical trials for a new four-dose rabies vaccination schedule, which is recommended by WHO and aims to improve patient convenience [5][6]. - The company is also monitoring opportunities in the animal vaccine market, although it has currently paused its animal rabies vaccine project [5][6].

Group 1: Impact of COVID-19 on Revenue - The COVID-19 pandemic significantly affected revenue in key sales regions such as Shanghai and the Yangtze River Delta, with a notable impact on the company's performance in Q1 2022 [1][2] - The company reported a decline in sales due to the pandemic, particularly in the domestic rabies vaccine market, but expects recovery as the situation stabilizes [2][3] Group 2: Market Position and Competition - The company remains a leading player in the domestic rabies vaccine market, maintaining strong competitive advantages in production technology, immunization processes, and brand value [2][3] - The international sales of rabies vaccines saw a decline due to pandemic-related disruptions, but recovery is anticipated as global conditions improve [2][3] Group 3: Product Development and Pipeline - The company is advancing its 15-valent HPV vaccine, which received clinical trial approval in March 2022, and is preparing for Phase I clinical samples [2][3] - The company plans to enhance the promotion of its Japanese encephalitis vaccine in 2022 to improve sales performance [2][3] Group 4: Financial Performance and Cost Management - The gross margin for rabies vaccines improved due to increased bidding prices, while sales expenses rose significantly due to heightened marketing efforts [3][4] - Despite increased sales expenses, the ratio of sales expenses to revenue remains low compared to industry standards, contributing positively to overall performance [3][4] Group 5: Future Strategies and R&D - The company is focusing on expanding its vaccine pipeline, including multi-valent and combination vaccines, while also considering market demand and national policy guidance [6][7] - Plans for international expansion are in place, targeting emerging markets while maintaining a strong position in the domestic market [6][7] Group 6: Sales and Marketing Structure - The domestic sales team consists of nearly 300 professionals, covering all provinces and municipalities in China, with a focus on providing quality service to disease control centers [3][4] - The company aims to strengthen its marketing team and enhance brand promotion to solidify its market share in rabies and Japanese encephalitis vaccines [3][4]